Return to search

The Osteogenic Effects of 12 Weeks of Oral Supplementation of Androstenedione in Middle-Aged Men.

Recent evidence suggests that declining bone mineral density (BMD) in males is related to declining circulating estrogens. The majority of endogenous plasma estrogens in males result from peripheral aromatization of plasma androgens. Thus, it was hypothesized that dietary supplementation with an aromatizable androgen (androstenedione) may stimulate increases in BMD.
BMD (measured by dual energy x-ray absorptiometry) and biochemical markers of bone turnover (1, 25 OH2 Vitamin D, calcitonin, deoxypyrodinoline, and parathyroid hormone) were assessed before and after 12 weeks of dietary androstenedione supplementation (200 mg/d). Twenty-four volunteers were randomized into either an androstenedione supplementation or placebo groups. Study volunteers also performed high intensity resistance training (RT) during the treatment period.
Androstenedione supplementation significantly increased plasma estradiol-17β levels by 82%. However, the increase in estradiol-17β did not impact bone turnover. The RT regimen did stimulate significant, local increases in BMD. Spine BMD was significantly increased by 6% for both treatment groups.

Identiferoai:union.ndltd.org:ETSU/oai:dc.etsu.edu:etd-1986
Date13 December 2003
CreatorsWills, Troy Matthew
PublisherDigital Commons @ East Tennessee State University
Source SetsEast Tennessee State University
Detected LanguageEnglish
Typetext
Formatapplication/pdf
SourceElectronic Theses and Dissertations
RightsCopyright by the authors.

Page generated in 0.0017 seconds